Stay updated on Safety of DCC-2618 in Advanced Malignancies Clinical Trial
Sign up to get notified when there's something new on the Safety of DCC-2618 in Advanced Malignancies Clinical Trial page.

Latest updates to the Safety of DCC-2618 in Advanced Malignancies Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedAdded a government funding notice and updated to v3.2.0; removed references to Mastocytosis, Gastrointestinal stromal tumor, and v3.1.0.SummaryDifference3%
- Check17 days agoChange DetectedUpdated page revision from v3.0.2 to v3.1.0; removed the older revision mention and the item 'Systemic mastocytosis'.SummaryDifference0.1%
- Check25 days agoChange DetectedNo changes detected: the page content remains as before.SummaryDifference0.3%
- Check32 days agoChange DetectedUpdated to revision v3.0.2 and removed the Back to Top element; no core content or critical information is affected.SummaryDifference0.2%
- Check39 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.5%
- Check46 days agoChange DetectedThe web page has been updated to include new drug information for Ripretinib and additional resources related to various types of neoplasms and diseases, while some previous location details and genetic resources have been removed.SummaryDifference6%
Stay in the know with updates to Safety of DCC-2618 in Advanced Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of DCC-2618 in Advanced Malignancies Clinical Trial page.